159 completed, 3 terminated, 2 active not recruiting, 1 recruiting. 152 Phase 1, 6 Phase 3, 3 Phase 2, 2 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 152 | Completed 149, Terminated 3 |
| Phase 3 | 6 | Completed 4, Active not recruiting 2 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Early Phase 1 | 2 | Completed 2 |
| Phase 4 | 1 | Completed 1 |
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigating Ovulation Inhibition for Use as a Contraceptive MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) - Contraception | Phase 2 | Recruiting | Mylan Pharmaceuticals Inc | 60 | 2025-12-22 | 2026-01-26 |
| Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential Transdermal system containing progestin - Female Contraception | Phase 3 | Active not recruiting | Mylan Pharmaceuticals Inc | 1630 | 2025-01-13 | 2026-10-13 |
| Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch MR-130A-01 Transdermal patch - Contraception | Phase 2 | Completed | Mylan Pharmaceuticals Inc | 168 | 2023-12-22 | 2024-11-29 |
| Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic) - COPD Exacerbation | Phase 4 | Completed | University of Tennessee Graduate School of Medicine | 60 | 2020-12-09 | 2026-08-03 |
| Extension Study of MYL-1701P-3001 for Safety and Efficacy MYL-1701P, a proposed biosimilar to Eylea - Diabetic Macular Edema | Phase 3 | Completed | Mylan Pharmaceuticals Inc | 52 | 2020-11-23 | 2026-08-03 |
| Revefenacin in Acute Respiratory Insufficiency in COPD Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide - COPD, Acute Respiratory Failure | Phase 2 | Completed | University of California, Los Angeles | 21 | 2020-11-01 | 2026-10-14 |
| Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME) MYL-1701P, Eylea - Diabetic Macular Edema | Phase 3 | Completed | Mylan Pharmaceuticals Inc | 355 | 2018-08-23 | 2023-03-07 |
| MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC Bevacizumab as MYL-1402O, Bevacizumab as Avastin - NSCLC Stage IV | Phase 3 | Completed | Mylan Pharmaceuticals Inc | 671 | 2017-01-21 | 2022-03-16 |
| The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. Fenofibrate, Inert lactose placebo - Type 1 Diabetes Mellitus, Diabetic Retinopathy | Phase 3 | Active not recruiting | University of Sydney | 412 | 2016-11-03 | 2026-01-20 |
| Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation Dexrazoxane - Heart Defects, Congenital | Phase 1 | Terminated | Medical City Children's Hospital | 12 | 2014-09-01 | 2018-07-26 |
| A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream, Placebo Vaginal Cream - Atrophic Vaginitis | Phase 3 | Completed | Mylan Pharmaceuticals Inc | 366 | 2014-06-01 | 2022-03-09 |
| A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act., Nasonex® Nasal Spray, 50 μg/actuation, Nasonex® Nasal Spray Suspnsn, 50 μg/actuation - Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 1307 | 2013-09-01 | 2014-04-09 |
| Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion Hercules, Herceptin EU, Herceptin US - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 132 | 2013-08-01 | 2015-11-03 |
| The Mycophenolate Pregnancy Registry Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases | Completed | Genentech, Inc. | 400 | 2012-11-20 | 2026-10-13 | |
| Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg) 1: Liothyronine Sodium Tablets, 2: Cytomel® Tablets - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 31 | 2007-10-01 | 2009-09-16 |
| Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg DEPAKOTE® Tablets, 500 MG, DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 17 | 2007-07-01 | 2010-08-18 |
| Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg DEPAKOTE® Tablets, 500 MG, DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 20 | 2007-07-01 | 2010-08-18 |
| Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg Nisoldipine Extended-release Tablets, 30 mg, Sular® Extended Release Tablets, 30 mg - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 78 | 2007-06-01 | 2009-09-28 |
| Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg, Parlodel® (bromocriptine mesylate) capsules, USP 5 mg - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 119 | 2007-05-01 | 2024-04-24 |
| Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg, Parlodel® (bromocriptine mesylate) capsules, USP 5 mg - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 120 | 2007-04-01 | 2024-04-24 |
Showing 20 of 165. Sign in to see all of them.
Atrophic Vaginitis (1) · Autoimmune Diseases (1) · Carcinoma, Non-Small-Cell Lung (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Diabetic Nephropathies (1) · Diabetic Retinopathy (1) · Dysuria (1) · Heart Defects, Congenital (1) · Nasal Obstruction (1) · Pruritus (1) · Pulmonary Disease, Chronic Obstructive (1) · Reperfusion Injury (1) · Retinal Diseases (1) · Rhinitis, Allergic, Seasonal (1)
Hydrochlorothiazide (9) · Metformin (8) · Tolterodine Tartrate (5) · Metoprolol (4) · Olmesartan Medoxomil (4) · Ondansetron (4) · Paroxetine (4) · Quinapril (4) · Thyroxine (4) · Valproic Acid (4) · benazepril (4) · Alprazolam (3) · Clarithromycin (3) · Doxycycline (3) · Metolazone (3)
United States (150) · Canada (8) · Germany (3) · India (3) · Hungary (2) · Poland (2) · Russia (2) · Australia (1) · Belarus (1) · Bosnia and Herzegovina (1) · Bulgaria (1) · Croatia (1) · Czechia (1) · Georgia (1) · Hong Kong (1)
Dorian Williams, M.D. (43) · James D Carlson, Pharm. D. (41) · Thomas S Clark, M.D. (23) · James Carlson, Pharm. D. (9) · Alan K Copa, Pharm. D. (4) · Eric Sicard, M.D. (3) · Bruce T Czarnik, M.D. (2) · Daniel Freeland, D.O. (2) · Gaetano Morelli, M.D. (2) · Lawrence Galitz, M.D. (2) · Paul Tam, MD (2) · Sandeep Jagtap (2) · So Ran Hong, M.D. (2) · Walter A Parham, M.D. (2) · Alan K Copa, Pharm.D. (1)
PMID 42373197, PMID 29926514, PMID 39264599, PMID 42104207, PMID 42548489